CVS Health Co. (NYSE:CVS) Shares Sold by Alpha Omega Wealth Management LLC

Alpha Omega Wealth Management LLC cut its stake in shares of CVS Health Co. (NYSE:CVS) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 138,075 shares of the pharmacy operator’s stock after selling 802 shares during the period. CVS Health accounts for about 1.8% of Alpha Omega Wealth Management LLC’s investment portfolio, making the stock its 6th biggest holding. Alpha Omega Wealth Management LLC’s holdings in CVS Health were worth $10,902,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Live Oak Investment Partners bought a new position in shares of CVS Health during the fourth quarter worth approximately $25,000. Atticus Wealth Management LLC increased its stake in shares of CVS Health by 149.0% during the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock worth $29,000 after purchasing an additional 219 shares during the period. Cornerstone Planning Group LLC increased its stake in shares of CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock worth $32,000 after purchasing an additional 243 shares during the period. PCA Investment Advisory Services Inc. bought a new position in shares of CVS Health during the second quarter worth approximately $37,000. Finally, ZRC Wealth Management LLC increased its stake in CVS Health by 400.0% during the 4th quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock worth $39,000 after acquiring an additional 400 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CVS Health

In related news, EVP Prem S. Shah sold 29,473 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $76.95, for a total value of $2,267,947.35. Following the completion of the transaction, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at $3,059,916.75. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.24% of the stock is currently owned by company insiders.

CVS Health Stock Performance

CVS stock traded up $0.07 during midday trading on Wednesday, reaching $69.03. 9,607,388 shares of the company’s stock traded hands, compared to its average volume of 8,555,254. The company has a 50-day moving average price of $75.68 and a two-hundred day moving average price of $73.77. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86. CVS Health Co. has a 52 week low of $64.41 and a 52 week high of $83.25. The firm has a market capitalization of $87.01 billion, a PE ratio of 10.69, a price-to-earnings-growth ratio of 0.91 and a beta of 0.52.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.11. The firm had revenue of $93.81 billion for the quarter, compared to analysts’ expectations of $90.58 billion. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.99 earnings per share. As a group, equities analysts anticipate that CVS Health Co. will post 8.32 EPS for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.85%. CVS Health’s dividend payout ratio is currently 41.18%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research analyst reports. Barclays began coverage on CVS Health in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 target price on the stock. Royal Bank of Canada lowered their price objective on CVS Health from $86.00 to $84.00 and set an “outperform” rating for the company in a research report on Thursday, February 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a research report on Wednesday, April 10th. HSBC began coverage on CVS Health in a research report on Friday, December 22nd. They issued a “buy” rating and a $94.00 price objective for the company. Finally, Leerink Partnrs reissued an “outperform” rating on shares of CVS Health in a research report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.